RxDoctor Payments DataLook up a doctor →

Michael Williams, MD

Urology · Virginia Beach, VANPI 1295058394

Payments from drug & device makers

$2,731,723in general payments, 2019–2025

Across 676 payments — averaging $4041.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$1.5M
  • Pfizer$460K
  • Janssen Research & Development, LLC$334K
  • Dendreon Pharmaceuticals LLC$222K
  • Ferring Pharmaceuticals Inc.$75K
  • Ferring Pharmaceuticals AS$69K
  • plus $55K from 34 others
$2,817in research payments, 2019–2025

Across 3 payments — averaging $939.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$2K
  • Pfizer$660

What the payments were for

  • Consulting fees$23,38216%
  • Speaking & faculty fees$95,66867%
  • Grants$1250%
  • Travel & lodging$13,90810%
  • Food & beverage$10,3037%
  • Education$2590%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,731,723 in reported general payments places this provider in the 95th percentile of 300 urology providers in Virginia.

See all urology providers in Virginia

Medicare billing

Part B allowed, 2024
$1,324,640
Medicare patients
1,348
Services billed
25,931

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide106$1,514,584
XtandiEnzalutamide63$658,907
NubeqaDarolutamide45$496,329
ZytigaAbiraterone Acetate12$132,375
Abiraterone Acetate85$89,596
OrgovyxRelugolix27$87,825
MyrbetriqMirabegron30$22,351
Trospium Chloride75$4,137
Tamsulosin Hcl299$4,093
Finasteride165$1,937
Oxybutynin Chloride ErOxybutynin Chloride53$1,089
Dutasteride25$872
Prednisone99$432
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav57$269
Doxazosin Mesylate14$234

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada, Zytiga$10,525$1,646,959118 claims
Astellas Pharma US IncXtandi, Myrbetriq$14,371$681,25893 claims
BayerNubeqa$778$496,32945 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$3,070$89,59685 claims
Sumitomo Pharma America, Inc.Orgovyx$37$87,82527 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 300 urology providers in Virginia.

Other urology in Virginia Beach

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →